BACKGROUND: Idiopathic pulmonary alveolar proteinosis (PAP) has recently been recognised as a disease of impaired alveolar macrophage function caused by neutralising anti-granulocyte-macrophage colony-stimulating (anti-GM-CSF) autoantibodies. Subcutaneous recombinant human GM-CSF is a novel treatment for PAP, but its mechanism of action is unclear. METHODS: Clinical, functional, and bronchoalveolar lavage (BAL) findings were prospectively evaluated in a patient with PAP treated with daily subcutaneous GM-CSF 8 microg/kg for 12 weeks. RESULTS: Treatment resulted in improvements in dyspnoea, lung function, and peak cycle ergometry performance. In serum and BAL fluid the titre of anti-GM-CSF autoantibodies was raised at baseline and markedly reduced on treatment. At baseline the BAL fluid cellular profile showed a decrease in the absolute number and the percentage of macrophages (50%) and an increase in lymphocytes (45%), predominantly CD4+. This cellular distribution remained unchanged after 6 and 12 weeks of treatment while macrophages became morphologically normal and functionally improved. Extracellular proteinaceous material completely disappeared. CONCLUSIONS: Clinically successful treatment of PAP with GM-CSF was associated with a profound reduction in GM-CSF neutralising autoantibodies, improvement in alveolar macrophage morphology and function, but persistent BAL lymphocytosis.
BACKGROUND:Idiopathic pulmonary alveolar proteinosis (PAP) has recently been recognised as a disease of impaired alveolar macrophage function caused by neutralising anti-granulocyte-macrophage colony-stimulating (anti-GM-CSF) autoantibodies. Subcutaneous recombinant humanGM-CSF is a novel treatment for PAP, but its mechanism of action is unclear. METHODS: Clinical, functional, and bronchoalveolar lavage (BAL) findings were prospectively evaluated in a patient with PAP treated with daily subcutaneous GM-CSF 8 microg/kg for 12 weeks. RESULTS: Treatment resulted in improvements in dyspnoea, lung function, and peak cycle ergometry performance. In serum and BAL fluid the titre of anti-GM-CSF autoantibodies was raised at baseline and markedly reduced on treatment. At baseline the BAL fluid cellular profile showed a decrease in the absolute number and the percentage of macrophages (50%) and an increase in lymphocytes (45%), predominantly CD4+. This cellular distribution remained unchanged after 6 and 12 weeks of treatment while macrophages became morphologically normal and functionally improved. Extracellular proteinaceous material completely disappeared. CONCLUSIONS: Clinically successful treatment of PAP with GM-CSF was associated with a profound reduction in GM-CSF neutralising autoantibodies, improvement in alveolar macrophage morphology and function, but persistent BAL lymphocytosis.
Authors: P Latzin; M Tredano; Y Wüst; J de Blic; T Nicolai; B Bewig; F Stanzel; D Köhler; M Bahuau; M Griese Journal: Thorax Date: 2005-01 Impact factor: 9.139
Authors: Grace Gathungu; Mi-Ok Kim; John P Ferguson; Yashoda Sharma; Wei Zhang; Sok Meng E Ng; Erin Bonkowski; Kaida Ning; Lisa A Simms; Anthony R Croft; Joanne M Stempak; Nicole Walker; Ning Huang; Yang Xiao; Mark S Silverberg; Bruce Trapnell; Judy H Cho; Graham L Radford-Smith; Lee A Denson Journal: Inflamm Bowel Dis Date: 2013-07 Impact factor: 5.325
Authors: Takuro Sakagami; David Beck; Kanji Uchida; Takuji Suzuki; Brenna C Carey; Koh Nakata; Gary Keller; Robert E Wood; Susan E Wert; Machiko Ikegami; Jeffrey A Whitsett; Maurizio Luisetti; Stella Davies; Jeffrey P Krischer; Alan Brody; Fred Ryckman; Bruce C Trapnell Journal: Am J Respir Crit Care Med Date: 2010-03-11 Impact factor: 21.405
Authors: Bruce C Trapnell; Yoshikazu Inoue; Francesco Bonella; Cliff Morgan; Stéphane Jouneau; Elisabeth Bendstrup; Ilaria Campo; Spyros A Papiris; Etsuro Yamaguchi; Erdogan Cetinkaya; Mikhail M Ilkovich; Mordechai R Kramer; Marcel Veltkamp; Michael Kreuter; Tomohisa Baba; Cecilia Ganslandt; Inge Tarnow; Grant Waterer; Taneli Jouhikainen Journal: N Engl J Med Date: 2020-09-07 Impact factor: 91.245